Gilteritinib (ASP2215)

Active substance

Gilteritinib (ASP2215)

Holder

Astellas Pharma Tech Co., Ltd.

Status

Running

Indication

treatment of patients with FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed or refractory acute myeloid leukemia (AML) without access to comparable or alternative therapy.

Public documents

Approbation

Approbation amendment

Information for the patient

Informed consent

Last update

27/04/2020

Last updated on 13/04/2021